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Abstract
Previous studies have shown that high total homocysteine levels are associated with Alzheimer’s disease (AD) and mild
cognitive impairment (MCI). In this study, we test the relationship between cognitive function and total homocysteine levels
in healthy subjects (Global Dementia Rating, CDR = 0) and individuals with MCI (CDR = 0.5). We have used a cognitive task
that tests learning and generalization of rules, processes that have been previously shown to rely on the integrity of the
striatal and hippocampal regions, respectively. We found that total homocysteine levels are higher in MCI individuals than in
healthy controls. Unlike what we expected, we found no difference between MCI subjects and healthy controls in learning
and generalization. We conducted further analysis after diving MCI subjects in two groups, depending on their Global
Deterioration Scale (GDS) scores: individuals with very mild cognitive decline (vMCD, GDS = 2) and mild cognitive decline
(MCD, GDS = 3). There was no difference among the two MCI and healthy control groups in learning performance. However,
we found that individuals with MCD make more generalization errors than healthy controls and individuals with vMCD. We
found no difference in the number of generalization errors between healthy controls and MCI individuals with vMCD. In
addition, interestingly, we found that total homocysteine levels correlate positively with generalization errors, but not with
learning errors. Our results are in agreement with prior results showing a link between hippocampal function, generalization
performance, and total homocysteine levels. Importantly, our study is perhaps among the first to test the relationship
between learning (and generalization) of rules and homocysteine levels in healthy controls and individuals with MCI.
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Introduction
Increasing number of studies has shown that homocysteine (a
compound found in the blood) is associated with mild cognitive
impairment (MCI), dementia, and Alzheimer’s disease (AD)
[1,2,3,4,5]. Based on these studies, in this project, we test the
relationship between homocysteine levels and cognitive function in
healthy controls and individuals with MCI. Unlike prior research
(which has mostly used questionnaires), here, we study the
relationship between homocysteine levels and learning and
generalization of rules.
Below, we discuss the neural and behavioral correlates of
homocysteine and MCI. Then, we review prior studies on the role
of the hippocampus and basal ganglia in learning and generaliza-
tion.
Homocysteine: neural and behavioral correlates
Previous studies have shown that total serum homocysteine
levels are associated with various brain disorders [1,2], including
Alzheimer’s disease [3,4,5,6,7], MCI [3,8], stroke [9], and
movement disorders [10]. Interestingly, it was found that baseline
measures of homocysteine levels in AD patients and healthy
subjects predict subsequent cognitive decline, as measured by the
Cambridge cognitive testing battery (CAMCOG) [11], mini-
mental state examination (MMSE), and the cognitive subscale of
the Alzheimer’s disease Assessment Tool (ADAS-Cog) [12]. Along
the same lines, studies suggest that low levels of homocysteine in
individuals with MCI are protective against conversion to
dementia [13].
Hyperhomocysteinemia is a condition associated with increased
levels of homocysteine in the blood. Interestingly, various studies
have shown that hyperhomocysteinemia is relatively more
common in AD patients than in controls [5]. Recently, Pirchl,
Ullrich, and Humpel [14] have found hyperhomocysteinemia is
associated with a reduction of cortical acetylcholine in rats.
Abnormal acetylcholine levels has been linked to AD and MCI
[15,16,17,18,19]; it is possible that increased levels of homocys-
teine leads to a reduction in acetylcholine levels, and thus cause
memory/cognitive symptoms of AD. In addition, recent research
has also shown that lowering homocysteine levels is neuroprotec-
tive in MCI [20]. Along the same lines, studies in rats found that
hyperhomocysteinemia is associated with impaired performance in
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the Morris water maze task [21,22], which tests spatial learning
and memory, and was found to rely on the hippocampus [23,24].
Importantly, recent clinical trials are investigating the therapeutic
efficacy of homocysteine-lowering drugs in AD patients (see www.
clinicaltrials.gov). These studies and clinical trials stress the
importance of understanding the relationship between homocys-
teine and cognition.
Studies measuring total homocysteine levels in healthy individ-
uals (especially in elderly populations) have shown that homocys-
teine plays an important role in cognitive processes
[25,26,27,28,29,30]. Specifically, Nurk et al. [25] found that
increased homocysteine levels in healthy individuals is associated
with impaired episodic memory performance. Along the same
lines, van de Kommer, Dik, Comijs, Jonker, and Deeg [31]
reported that higher homocysteine levels are associated with slow
information processing speed and fluid intelligence in healthy
adults. Also, Garcia, Haron, Pulman, Hua, and Freedman [32]
have shown that higher levels of homocysteine are correlated with
impaired performance in the Stroop test. Specifically, homocys-
teine was shown to be involved in episodic memory [3,33], spatial
learning [14], reversal learning [34,35], and executive function
[33]. On the other hand, studies have suggested homocysteine is
perhaps not associated with other cognitive processes, including
working memory and attention [33], although other studies
reported that lowering homocysteine levels enhance working
memory [36].
The exact function of homocysteine is not known. However,
prior studies have shown that homocysteine acts on various brain
regions, including the hippocampus [37,38,39], cortex [39], and
the basal ganglia [40]. Higher homocysteine levels lead to atrophy
in the frontal, parietal, and temporal areas [41]. Also, various
studies have suggested that homocysteine might regulate the
function of other neuromodulators, such as acetylcholine [37] and
dopamine/serotonin [22]. Specifically, Gao et al. [22] have
reported that rats with hyperhomocysteinemia have lower level of
dopamine and serotonin in the cortex than control rats. Other
studies suggest that homocysteine regulates synaptic plasticity in
the hippocampus [34,35]. These prior studies suggest that
homocysteine has multiple functions in the brain.
Mild cognitive impairment
Mild cognitive impairment (MCI) is a state of cognitive decline
greater than that expected for an individual’s age and education
level, but falling short of dementia [42]. Individuals with MCI are
statistically at increased risk to develop AD within the next several
years [43,44], which suggests that MCI may reflect gradual
accumulation of AD pathology, though at a level not yet sufficient
to cause catastrophic decline in cognitive function. This is
particularly true of the MCI subgroup with memory loss as a
predominant syndrome, a condition termed amnestic MCI [45].
Studies suggest that individuals with MCI tend to progress to AD
at a rate of 10–15% per year [46,47,48], and many researchers
consider MCI to be an early or prodromal form of AD.
The role of the basal ganglia and hippocampus in
learning and generalization
Prior research has shown that learning of rules and generaliza-
tion of these rules in new contexts are subserved by different brain
systems.
Several studies have shown that the basal ganglia is involved in
learning from corrective feedback [49]. In feedback learning tasks,
subjects learn to associate the presentation of different stimuli with
different responses, based on corrective feedback. For example,
animal literature has also shown that striatal cells show increased
activity during stimulus-response learning [50]. Also, fMRI studies
have shown basal ganglia is active in during feedback learning
tasks [49,51]. Along the same lines, patients with Parkinson’s
disease patients (disease associated with basal ganglia dysfunction)
show impairment at the learning phase of the same task used here
[52]. Using various learning tasks, studies show that dopamine
medications and agents impair learning in both Parkinson’s disease
patients [53,54], possibly by affecting the basal ganglia structure.
Recent reviews by Seger and colleagues provide extensive
discussion on the role of the basal ganglia in learning [55,56].
The hippocampus participates in the generalization of learned
rules [57,58,59,60]. Patients with hippocampal damage are
impaired at retrieving information when study and test conditions
are different [61,62,63]. Other research has shown that the
hippocampus is important for the generalization of learned rules in
various paradigms, including transitive inference, sensory precon-
ditioning, and acquired equivalence (which we describe below).
For example, several studies have shown that the hippocampus is
involved in transitive inference, in which subjects learn to deduce
new information from previously learned rules (e.g., if A.B &
B.C, we conclude that A.C) [64,65]. Using fMRI, Shohamy
and colleagues [60] have found that the hippocampus is active
while subjects performing the sensory preconditioning task, in
which if a subject is first given unreinforced trials with stimuli A
and B presented together as a compound cue (AB -), then training
the subject that A (alone) predicts a certain outcome will lead some
of this association to be transferred to B—that is, subjects also
learn that B predicts the same outcome as A [66]. Shohamy and
colleagues found that the hippocampus is important for general-
ization of rules in this paradigm.
Another paradigm that involves generalization of rules is the
acquired equivalence task. In this task, stimuli become equivalent
when they are associated with the same outcome [67]. For
example, if cue A is associated with outcome C, and cue B is also
associated with the same outcome C, subjects learn that A and B
are associated (which is a gernalization from previously learned
rules). Research at our lab has shown that hippocampal atrophy
interferes with generalization performance in the acquired
equivalence task [62]. Similarly, rats trained to choose among
two odors (A or B in some trials, or C or D in other trials), based
on reinforcement given to the choice of one of them (A in AB
trials, or C in CD trials) would generalize well to novel pairing of
familiar odors, that is, they will choose A in AD trials, and C in CB
trials. However, animals with hippocampal dysfunction performed
at chance on these novel pairings [57]. The learning-and-
generalization task used in our study is an example of such
generalization task and is similar to the animal study used by
Eichenbaum and colleagues [57], in that subjects learn to
generalize to previously learned rules (see description below). We
have recently found that the hippocampus is active in elderly but
not in MCI subjects while performing learning-and-generalization
tasks [68]. These prior data show that the hippocampus
participates in generalization of learned rules in various experi-
mental paradigms.
In sum, prior studies suggest that learning and generalization of
learned rules are subserved by different brain systems, namely the
basal ganglia and hippocampus. In the current study, we test if
these cognitive processes are affected by homocysteine levels in
healthy controls and individuals with MCI.
Methods
Below, we describe details on subject recruitment, neuropsy-
chological assessment, the measures of homocysteine levels from
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blood samples collected from all subjects, and the computerized
learning-and-generalization task.
Subjects
All subjects were screened based on self-reports for medical or
psychiatric history, including presence of depression, multiple
sclerosis, aphasia, and seizure/epilepsy. We also excluded subjects
who showed signs of dementia. We recruited 59 individuals from
the department of Psychiatry, Ain Shams University. All subjects
signed statements of informed consent before testing was initiated.
Research conformed to guidelines for protection of human
subjects established by Ain Shams University’s School of
Medicine. Ethics committee at Ain Shams University’s School of
Medicine approved this study.
Neuropsychological Assessment
We screened subjects who complained of subjective memory
impairment using the mini-mental status examination (MMSE)
which is a screening test to prove that subjects are not suffering
from definite memory impairment [69]. We excluded 4 subjects
who had low MMSE scores (less than 24) or appear to show signs
of dementia as observed by the neurologists (D.H.H and A.M.E).
We then conducted the Clinical Dementia Rating (CDR) scale,
which was designed to identify the degree and severity of dementia
in human subjects [44,70,71]. The CDR evaluates problem
solving abilities, orientation in time and place, personal care skills,
home activities, among others. The CDR scores range from 0 to 3,
and indicate no dementia (CDR = 0), mild cognitive impairment
(MCI; CDR = 0.5), mild dementia (CDR = 1), moderate dementia
(CDR = 2) or severe dementia (CDR = 3). As in previous studies,
all controls in our study had Clinical Dementia Rating (CDR) of 0,
while individuals with MCI have CDR of 0.5 [70,72].
In addition, we assessed all subjects for cognitive impairments
using the Global Deterioration Scale (GDS) [73,74] which ranks
individuals according to a 7-point scale. The GDS 1 rating is given
to an individual with no memory impairment. The GDS 2 rating
is given to an individual who is functionally unimpaired but with
subjective complaints of mild forgetfulness that is not recognized
by family members or coworkers and for which there is no clinical
evidence. The GDS 2 score refers to a condition known as very
mild cognitive decline (vMCD). The GDS 3 rating is given to an
individual with subtle functional deficits, revealed with extensive
clinical interview. Whereas GDS 3 rating does not indicate
dementia, individuals with GDS 3 ratings are at heightened risk to
subsequently develop AD, compared with individuals given GDS
ratings of 1 and 2 [43,75]. The GDS 3 score refers to a condition
known as mild cognitive decline (MCD). GDS rating of 4 and
higher indicate dementia with increasingly severe cognitive and
functional impairments; GDS 4 is often considered indicative of
mild AD. To be included in the current study, individuals were
required to have ratings of GDS 3 or lower, indicative of
nondemented clinical status. In total, we excluded 3 subjects who
had dementia (as measured by CDR or GDS).Overall, subjects in
the current study had an average GDS rating of 1.93 (SD = 0.68).
The final sample consisted of 52 subjects who scored at or above
age-appropriate norms on standardized neuropsychological tests.
These 52 participants were administered the learning-and-
generalization task. We have excluded another 3 subjects who
did not pass the criterion in the learning phase of the task (see
description below). Results for the 49 participants are shown in
Table 1.
Homocysteine levels
We have collected blood samples from all subjects who passed
the neuropsychological screening tests mentioned above (N = 52)
to measure plasma homocysteine levels using the Homocysteine
Enzyme Immunoassay (EIA) method, as outlined in prior studies
[76]. This is an enzyme immunoassay for the determination of
homocysteine in blood. Specifically, in all healthy controls and
MCI individuals, venous blood samples (maximum 2 cm3) were
withdrawn and put in EDTA anticoagulated tubes to prevent
blood clotting. All blood samples were put on ice immediately after
drawing for up to 6 hours prior to separation of plasma by
centrifugation. Reagents were added to the plasma, which was
then kept at room temperature (18–25uC) to avoid destruction of
enzymes. In prior studies, higher homocysteine levels have been
associated with dementia and cognitive impairment [5,30,77].
Here, we tested whether homocysteine levels correlate with
performance in the learning-and-generalization task.
Cognitive task: Learning-and-Generalization
Here we describe details of the learning-and-generalization task.
Testing took place in a quiet room at Ain Shams’s School of
Medicine, with the subject seated in front of a Macintosh
MacBook laptop computer with color screen. The keyboard was
masked except for two keys, labeled ‘‘LEFT’’ and ‘‘RIGHT’’
which the subject used to enter responses.
The task has two phases: learning and generalization. The
learning phase of the task consists of an eight-pair concurrent
discrimination. This is an incrementally-acquired, feedback-based
learning task in which subjects are to learn, via feedback, which
object is correct, and they are given no information about the
correct object ahead of time. On each trial, two colored shapes
appeared, approximately 10 in height on the screen and set about
30 apart (approximately 1.5 degrees of visual angle, at normal
viewing distance). The subject was instructed to press the left or
right key to choose one object. The chosen object was raised and,
if the choice was correct, a smiley face was revealed underneath
(see Figure 1). There was no limit on response time, and there was
an interval of approximately one second between subject response
and start of the next trial, allowing the subject to view the
discrimination pair together with feedback (presence or absence of
the desired smiley face icon).
Within each object pair, the same object was always rewarded.
For four of the discrimination pairs, objects differed in shape but
not color (e.g. brown mushroom vs. brown frame); for the
remaining four pairs, objects differed in color but not shape (e.g.
red cat’s-eye vs. yellow cat’s-eye). Thus, within each pair, one
dimension (color or shape) was relevant with respect to predicting
the location of the smiley face, and one dimension was irrelevant.
Trials were organized into blocks, each containing 16 trials: one
presentation of each discrimination pair in each possible left-right
ordering. Trials in a block occurred in a pseudorandom but fixed
order. Phase 1 continued until the subject reached a criterion of 16
consecutive correct responses, or for a maximum of 96 trials (6
blocks).
After the learning phase, the generalization phase began
without any warning to the subject. The screen events were
identical to the learning phase except that the discrimination pairs
were altered so that the relevant features remained constant but
the irrelevant features were altered. Thus, for example, the
learning phase discrimination in which a brown mushroom was
rewarded over a brown frame became in the generalization phase
a discrimination in which a green mushroom was rewarded over a
green frame. Similarly, the learning phase discrimination in which
a red cat’s-eye was rewarded over a yellow cat’s-eye became in the
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generalization phase a red/yellow discrimination involving a new
shape. Individuals who had previously solved the learning phase
by basing associations on the relevant features (mushroom beats
frame and red beats yellow) could perform perfectly in the
generalization phase, since the relevant features are still predictive.
By contrast, individuals who had approached the learning phase
by learning to respond to whole objects (brown-mushroom beats
brown-frame) should perform poorly in the generalization phase
where there are novel objects (green-mushroom and green-frame).
Generalization phase trials were organized into blocks of 16
trials, one trial with each discrimination pair in each possible left-
right ordering, in a pseudorandom but fixed order. The
generalization phase continued until the participant reached a
criterion of 16 consecutive correct responses, or to a maximum of
48 trials (3 blocks). The entire procedure took approximately 15–
20 minutes to complete.
Results
For all analyses, we used SPSS and SAS v8.0 PROC MIXED to
examine between-subject differences, using unstructured covari-
ance matrices (which does not make any strong assumptions about
the variance and correlation of the data, as do structured
covariances).Where indicated, we tested for specific planned
contrasts. In these contrasts, the number of degrees of freedom
reflects the entire sample, and not just the subjects involved in the
particular contrast, because the mixed procedure analyzes
between-subject effects, and controls for other variables of interest
that apply across all subjects. This procedure uses all of the data to
provide a more stable estimate of the error term.
Healthy controls vs. individuals with mild cognitive
impairment
As mentioned above, for the purposes of analyses, subjects were
divided into two groups: Healthy controls (CDR = 0) and
individuals with MCI (CDR = 0.5).
We found that only one healthy subject finishes the acquisition
phase in five blocks (80 trials), while the rest of subjects took all six
blocks (96 trials). In the generalization phase, all subjects took all
48 trials. This means that most subjects have done more or less the
same number of trials throughout the task.
In addition, we tested if there were any differences among the
subjects on (a) homocysteine levels and (b) number of errors in the
learning and generalization phases. We found there is a significant
effect of group on homocysteine levels (p , 0.001), such as
homocysteine levels are significantly higher in individuals with
MCI than in healthy controls (Figure 2). However, there was no
effect of group on either learning (p.0.2, Figure 3A) or
generalization performance (p.0.1, Figure 3B).
To test for learning effects, we divided performance into
different blocks (each is 24 trials). One subject did 80 trials in the
acquisition phase (with blocks has 20 trials each). We found that
across all subjects, there was an effect of block in the learning
(p = .001) but not generalization phase (p = 0.12). Same effects of
block was correct for all groups (p’s , = 0.04; see Figure 4). In
addition, there was no difference between MCI and controls in
any of the blocks in acquisition or generalization phases.
In addition, we did not find significant difference in reaction
time (RT) among all groups in either acquisition or generalization
phases (Figure 5, all p’s.0.12). This is perhaps because the task
allowed subjects unlimited time to respond on each trial, and thus
there was no time constraints. Accordingly, we believe that our
task does not assess speed vs. accuracy measures. In order to assess
this measure, tasks should include limitation on response time
allowed for subjects [78]. Importantly, most learning and decision
making studies usually report number of errors during acquisition.
Effects of severity of mild cognitive decline on cognitive
and homocysteine measures
Given that we found no difference among the control and MCI
groups in learning and generalization, we reasoned that severity of
MCI symptoms as measured by GDS might reveal differences in
learning and generalization. Here, we have conducted further
statistical analysis after dividing the MCI group into two
subgroups: those with GDS = 2 (very mild cognitive decline,
vMCD), and those with GDS = 3 (mild cognitive decline, MCD).
Table 1. Demographic information of healthy controls and individuals with MCI in the learning-and-generalization study.
Group N n filt Sex ratio (m:f) Age Years Education CDR GDS MMSE
Controls 26 24 11:13 66.3 (5.18) 13.1 (1.34) 0 1.4 (0.51) 27.7 (1.45)
MCI 26 25 10:15 69.1 (6.42) 12.7 (1.56) 0.5 2.4 (0.50) 26.2 (1.72)
Abbreviation: n is number of subjects we tested; n filt is number of subjects after filtering out subjects who did not learn the task; CDR is clinical dementia rating; GDS is
global deterioration scale; MMSE is mini mental status examination.
doi:10.1371/journal.pone.0046496.t001
Figure 1. Screen events on a sample trial of phase 1. (A) At start of trial, two objects appear, differing in color or shape but not both. (B) The
participant chooses one object and that object is raised; if the choice was correct, a smiley face is revealed underneath. C) If incorrect, there is no
smiley face.
doi:10.1371/journal.pone.0046496.g001
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As before, the dependent variables included number of errors in
the learning and generalization phases, and homocysteine levels.
First, we found no difference among the MCI groups (vMCD
vs. MCD) in age or education level (p.0.1). In addition, we found
that both vMCD and MCD groups have larger homocysteine
levels than controls (p ,0.03 & p , 0.02, respectively). Unlike
what we expected, there was no effect of MCI severity (based on
GDS rating) on homocysteine levels (p.0.1, Figure 6). As for
cognitive performance, there was no effect of group or MCI
severity on the number of errors in the learning phases (Figure 7A).
Interestingly, we found that individuals with MCD made
significantly more errors in the generalization phase than either
individuals with vMCD (p , 0.01) or healthy controls (p , 0.02)
(see Figure 7B). There was no difference between vMCD and
healthy individuals in the number of errors in the generalization
phase (p.0.2).
To rule out the possibility that learning phase performance
affects generalization phase performance, we subtracted of
number of errors in the learning phase from the number of errors
in the generalization phase (generalization – learning) for each
subject in the MCI subgroups and healthy control individuals.
Here, we found that the generalization-learning performance in
the MCD group were less negative than in vMCD or healthy
controls (p , 0.03; Figure 8). Less negative values in the
generalization-learning measure stem from comparable perfor-
mance in learning and generalization. In the MCD group, less
negative generalization-learning measure is due to a high number
of errors in the generalization phase.
Correlations of homocysteine levels and learning and
generalization of rules
Lastly, we conducted correlational analyses between number of
errors in the learning and generalization phases and homocysteine
levels. As predicted, we found no significant correlation between
homocysteine levels and learning performance (Figure 9A,
r = 20.12, p.0.3). In contrast, we found a significant positive
correlation between homocysteine levels and generalization errors
(Figure 9B, r = 0.482, p , 0.001). We also found a negative
correlation between homocysteine levels and MMSE scores
(Figure 10, r = 20.414, P ,0.002).
Give that there was an effect of group on generalization
performance, we additionally conducted a multiple regression
analysis, with number of errors in the generalization phase as the
dependent variable, and homocysteine levels, GDS and CDR as
predictors. The overall regression was significant (p,.0005,
R2 = 0.547). Controlling for the GDS and CDR levels, the effect
of homocysteine levels on the number of errors in the generaliza-
tion phase was significant (B = 1.25, p = .005). In addition, once
the other factors were controlled, there were no significant effects
of GDS or CDR, and no interactions (all p’s.0.1).
Discussion
To our knowledge, this is the first study to test the relationship
between homocysteine levels and learning/generalization of rules
in healthy subjects and individuals with MCI. Most prior studies
that have shown homocysteine levels to be correlated with
cognitive performance have used questionnaires, and thus could
not assess learning performance [12].
Our results show that homocysteine levels are higher in
individuals with MCI than in healthy controls. Using a comput-
erized learning-and-generalization task to test for striatal and
hippocampal function, we found no difference in learning and
generalization performance in healthy controls and individuals
with MCI. We have divided MCI individuals (CDR = 0.5) into two
Figure 3. Learning and generalization performance in MCI and healthy control individuals. We have found no difference between MCI
and HC either in the number of errors the learning (A) or generalization phase (B).
doi:10.1371/journal.pone.0046496.g003
Figure 2. Total homocysteine levels are higher in individuals
with MCI than in controls. HC = healthy controls.
doi:10.1371/journal.pone.0046496.g002
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groups, based on the severity of their symptoms, as measured by
the GDS. All of our MCI subjects have GDS of 2 or 3. We have
found that individuals with MCD made more errors in the
generalization phase than individuals with vMCD. There was no
difference between the MCI subgroups on the learning phase of
the task. Unlike what we expected, we found that homocysteine
levels are not significantly different in both MCI groups. Finally,
we found that there is a positive correlation between homocysteine
levels and generalization errors. We found no correlation between
homocysteine levels and learning performance. Our data suggest
that dividing individuals with MCI based on measures such as
GDS can be informative in terms of their cognitive deterioration
and potentially hippocampal dysfunction. We also suggest that
hippocampal dysfunction might be stronger in individuals with
MCD than in individuals with vMCD. Importantly, our data also
show that plasma blood measures can be indicative of cognitive
function in individuals with MCI.
The finding that there was no differential effects among
individuals with vMCD and healthy individuals suggest that signs
of cognitive impairment in MCI might perhaps appear in more
severe cases only. One implication of our results is that although
individuals with vMCD show no impairment on the cognitive
learning-and-generalization tasks (as compared to healthy con-
trols), they have a homocysteine profile that looks like individuals
with MCD. This perhaps suggest that homocysteine levels can be a
biological marker for MCI in that it can differentiate between
healthy controls and individuals with vMCD.
Along the same lines, prior research has suggested that AD
involves neural dysfunction that begins before onset of symptoms.
It is possible, in our study, that individuals with MCD, were in the
prodromal stages of AD. A follow up of these people on clinical
and neuropsychological measures would help to verify whether
they have prodromal AD.
Neural substrates of generalization, homocysteine effect,
and MCI
In this section, we discuss studies that address the neural
substrates (including the hippocampus and prefrontal cortex) of
generalization performance, homocysteine effect, and MCI.
Our results are in agreement with prior results showing that
hippocampal atrophy is associated with impaired performance in
the generalization phase of our task [62]. In a prior study, we also
found some older healthy individuals (with potential hippocampal
dysfunction) show impaired performance in the generalization
phase [79]. Our results are also in agreement with a wealth of
studies reporting impaired hippocampal-based cognitive perfor-
mance in individuals with MCI [80,81,82,83,84].
Extensive literature has linked generalization performance to
the function of the hippocampus, using various behavioral
Figure 5. Reaction time in the learning and generalization task in MCI and healthy control individuals. We have found no difference
between MCI and HC in RT in the learning (A) or generalization (B) phase.
doi:10.1371/journal.pone.0046496.g005
Figure 4. Mean total of errors in the learning and generalization task in MCI and healthy control individuals. We found an effect of
block in both groups in the learning but not generalization phase. As in prior analysis, by adding block number as a variable in ANOVA analysis, we
found no difference between MCI and HC either in the number of errors the learning (A) or generalization phase (B).
doi:10.1371/journal.pone.0046496.g004
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paradigms including transitive inference, generalization of learned
rules, sensory preconditioning, and acquired equivalence
[57,58,59,60,62,65]. In addition, recent studies have also shown
a relationship between the hippocampus and generalization of
rules in language learning [85]. Importantly, computational
modeling and theoretical studies also explain how the hippocam-
pus might mediate generalization processes [86,87,88].
Unlike the hippocampus (which plays a role in generalization),
some studies report that the prefrontal cortex plays a role in both
learning and generalization [see for example 89]. It is possible that
the prefrontal cortex participates in the maintenance of rules in
working memory, processes that might explain its function in both
learning and generalization of rules. For example, recently, Collins
and Frank [90] found that working memory plays an important
role in rule learning, although we are not aware that establishes a
link between working memory and generalization performance.
Similarly, most existing studies found that variations in
homocysteine level affect the hippocampus [37,38,39]. However,
some studies also found that homocysteine acts on the cortex [39],
and that hyperhomocysteinemia lead to atrophy in the prefrontal
cortex [41]. These studies suggest that homocysteine has a
complex effect on the brain. It is not clear whether homocysteine
effect on the prefrontal cortex has any relationship to our
behavioral results. However, given prior results on the same task,
we assume that homocysteine effects on the hippocampus are
responsible for the differences in generalization performance in
healthy and MCI subjects.
Along the same lines, MCI might have a more complex effect
on the brain than assumed here. In the current study, we focused
on the effect of MCI on the hippocampus, which is in agreement
with an extensive body of literature. For example, individuals with
MCI who show hippocampal atrophy on structural imaging are at
heightened risk for incipient cognitive decline and AD, relative to
nonatrophied subjects [82,83]. The hippocampus and related
medial temporal lobe structures, including entorhinal cortex, show
pathology very early in the course of AD [81,84,91,92]. Also,
individuals with MCI show impairment on hippocampal-based
cognitive tasks, including declarative memory [80].
In addition to the hippocampus, studies found that the
prefrontal cortex also deteriorates in individuals with MCI and
AD [93,94]. In addition, some empirical studies argue that
prefrontal dysfunction in individuals with MCI might be caused by
a disconnection from the hippocampus [95].
Based on previous studies linking generalization impairment to
the hippocampus [58,60,62,65,96], it is plausible that our results
are more associated with hippocampal rather than prefrontal
dysfunction. In addition, our prior theoretical model [88] shows
how generalization deficits can stem from a simulated hippocam-
pal dysfunction in individuals with dementia.
Future research should test whether homocysteine affect
cognitive processes associated with the prefrontal cortex, and test
whether increased homocysteine levels in the prefrontal cortex
contribute to cognitive dysfunction in MCI and AD.
Clinical implications
There are many definitions of MCI in the literature
[73,97,98,99]. Two commonly used clinical definitions of MCI
in the literature are CDR or GDS measures. Some studies define
MCI based on a CDR score of 0.5 [70,72], while others define
MCI based on GDS score of 3 [43,75]. In our study, we found that
defining MCI based on CDR scores allows for variability in GDS
ratings. Specifically, we found that some of our MCI subjects
(CDR = 0.5) have GDS scores of 2 or 3 [for similar results, see 47].
Figure 7. Learning and generalization performance in MCI subgroups and healthy control individuals. (A) The healthy control (HC),
vMCD, and MCD groups made similar number of errors during learning; (B) however, on generalization, the MCD group made more generalization
errors than controls and individuals with vMCD.
doi:10.1371/journal.pone.0046496.g007
Figure 6. Homocysteine levels in MCI subgroups and healthy
controls. Unlike what we expected, there was no effect of MCI severity
(that is, between vMCD and MCD) on total homocysteine levels. As
before, homocysteine levels in both MCI subgroups are higher than in
healthy controls (HC).
doi:10.1371/journal.pone.0046496.g006
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The opposite was not true: in our study, all subjects with MCD
have CDR score of 0.5. Importantly, we also found that subjects
with vMCD and MCD show different cognitive performance,
particularly in the hippocampal-based generalization phase of our
task. According to Flicker et al. [43], subjects with GDS score of 3
are either MCI or mildly demented. Interestingly, Petersen et al
[47] have found that subjects classified with MCI using clinical
criteria have either GDS of 2 or 3. These Petersen et al. findings
are similar to ours in that various clinical definitions of MCI do not
always match.
There have been conflicting results on the relationship between
MCI and homocysteine levels. Some studies reported elevated
homocysteine levels in MCI individuals [8], while others do not
report this association [100]. These conflicting findings could
perhaps be related to the various ways MCI is identified. In the
Kim et al. [8] and Reitz et al. [100] studies, MCI was diagnosed
by a consensus of neurologists and clinical tests based on DSM-IV
criteria, rather than using CDR or GDS measures.
The implications of our findings are that it is important to take
into account the degree of cognitive impairment in individuals
with MCI. Future research should address rates of conversion to
AD among subgroups of individuals with MCI. Our work suggests
that conversion rate might be higher in individuals with MCD
than individuals with vMCD. In addition, low levels of homocys-
teine combined with low GDS rating should be protective against
conversion to dementia in individuals with MCI (and perhaps
more so in individuals with vMCD than in individuals with MCD).
Future work should test this hypothesis.
Our future work includes building a computational neural
network model of the hippocampal region and basal ganglia
interactions (following earlier models, see for example [88]) to
explain (a) how homocysteine is important for cognitive processes
(by linking this to homocysteine effects on acetylcholine and
synaptic plasticity in the hippocampus). We will use the model to
explain how increased homocysteine levels impair cognition in
MCI and AD patients. Christie et al. [35] have found chronic
exposure to homocysteine in rats impairs synaptic transmission. In
our model, we will simulate impaired synaptic transmission by
disrupting weights (simulated synapses) connecting nodes (simu-
lated neurons) in the simulated hippocampal region.
Many studies have reported that lowering homocysteine levels
enhances memory and cognition in individuals with MCI and AD
[20,101]. Future work at our lab will investigate whether
homocysteine-lowering compounds (such as B12 vitamin supple-
Figure 9. Total homocysteine levels correlate with the number of errors in the generalization phase (B), but not with the number of
errors in the learning phase (A).
doi:10.1371/journal.pone.0046496.g009
Figure 8. The subtraction of number of errors in learning from
generalization (generalization – learning) in MCI subgroups
and healthy control individuals. In almost all subjects, this measure
is negative since subjects tend to make more errors in the learning than
in the generalization phase. Interestingly, the generalization-learning
performance in the MCD group were less negative than in vMCD or
healthy controls (p , 0.03). Less negative values in the generalization-
learning measure stem from comparable performance in learning and
generalization. In the MCD group, less negative generalization-learning
measure is due to a high number of errors in the generalization phase.
doi:10.1371/journal.pone.0046496.g008
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ments) has an effect on the learning-and-generalization task in
individuals with MCI and AD.
In sum, our study is perhaps among the first to test the
relationship between homocysteine levels and learning and
generalization of rules in healthy controls and individuals with
MCI. We found that individuals with MCD, but not with vMCD,
show impairment at the generalization of rules. We also found
increased homocysteine levels correlate with increased number of
generalization errors. These findings are in agreement with data
showing hippocampal dysfunction in MCI.
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